Estrogen Therapy Linked to 39% Lower Dementia Risk

Women who used estrogen therapy later in life showed remarkably healthier brains and lower rates of dementia, according to research that could reshape how we think about brain health in aging.

The large study, published in Neurology, examined brain scans, biomarker tests, and autopsy results from 21,462 women. Among those who used estrogen-only hormone therapy, 18% showed no signs of Alzheimer's disease at autopsy, compared to just 10% of non-users.

The findings revealed something even more striking. Among women who used hormone therapy, 40% showed all three major signs of Alzheimer's disease, while 51% of non-users showed these markers. That difference represents a 35% reduction in the odds of developing Alzheimer's-related brain changes.

Lead researcher Dr. Jennifer Bruno from Stanford Medicine emphasized that these results show an association, not proof that hormone therapy prevents dementia. However, the consistency across multiple measurements strengthens the findings.

Blood and spinal fluid tests painted a similar picture. Women who used hormone therapy had biomarker levels indicating less amyloid protein building up in their brains as harmful plaques. These proteins are a hallmark of Alzheimer's disease.

The study also found that hormone therapy users had 39% lower odds of receiving a dementia diagnosis. They showed fewer memory problems and maintained their ability to handle everyday tasks better than non-users.

Why This Inspires

This research offers hope to millions of women navigating decisions about aging and brain health. While the women in this study used hormone therapy differently than current practice recommends, the clear association between estrogen and brain protection opens new avenues for understanding dementia prevention.

The study examined only estrogen-only therapy, which is currently prescribed mainly to women who have had hysterectomies. Earlier research suggested that combined estrogen-progestin therapy might increase dementia risk, making this distinction crucial.

Dr. Bruno noted an important limitation: the women studied began hormone therapy around age 70, while current practice typically involves starting in the late 40s to early 50s. More research is needed to understand how timing affects brain health outcomes.

This finding builds our understanding of how hormones protect the aging brain and could guide future treatments specifically designed for dementia prevention.